VENLAFAXINE HYDROCHLORIDE capsule, extended release
国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
资料单张 有效成分:
VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG)
可用日期:
Major Pharmaceuticals
给药途径:
ORAL
处方类型:
PRESCRIPTION DRUG
疗效迹象:
Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of major depressive disorder (MDD). Efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. Venlafaxine hydrochloride extended-release capsules, USP is indicated for the treatment of Generalized Anxiety Disorder (GAD). Efficacy was established in two 8-week and two 26-week placebo-controlled trials. Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of Social Anxiety Disorder (SAD), also known as social phobia. Efficacy was established in four 12-week and one 26-week, placebo-controlled trials. Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of Panic Disorder (PD), with or without agoraphobia. Efficacy was established in two 12-week placebo-controlled trials. Hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation The use of MAOIs (intended
產品總結:
Venlafaxine hydrochloride extended-release capsules, USP are available as follows: 37.5 mg, size "4" hard gelatin capsule with grey cap and peach body printed with "37.5" on the body and "1018" on the cap with red ink containing white to off white pellets. Carton of 100 tablets (10 tablets each blister card x 10) NDC 0904-6468-61 75 mg, size "1" hard gelatin capsule with pink cap and body printed with "75" on the body and "1019" on the cap with red ink containing white to off white pellets. Carton of 100 tablets (10 tablets each blister card x 10) NDC 0904-6469-61 150 mg, size "0" hard gelatin capsule with orange cap and body printed with "150" on the body and "1020" on the cap with white ink containing white to off white pellets. Carton of 100 tablets (10 tablets each blister card x 10) NDC 0904-6470-61 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight container with a child-resistant closure.
授权状态:
Abbreviated New Drug Application
资料单张
VENLAFAXINE HYDROCHLORIDE- VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED
RELEASE
Major Pharmaceuticals
----------
MEDICATION GUIDE
Venlafaxine Hydrochloride (VEN-la-FAX-een HYE-droe-KLOR-ide)
Extended-Release Capsules, USP
Read the Medication Guide that comes with venlafaxine hydrochloride
extended-release capsules before
you start taking it and each time you get a refill. There may be new
information. This Medication Guide
does not take the place of talking to your healthcare provider about
your medical condition or treatment.
Talk with your healthcare provider if there is something you do not
understand or want to learn more
about.
What is the most important information I should know about venlafaxine
hydrochloride extended-release
capsules?
Venlafaxine hydrochloride extended-release capsules and other
antidepressant medicines may cause
serious side effects, including:
1. Suicidal thoughts or actions:
•
Venlafaxine hydrochloride extended-release capsules and other
antidepressant medicines may
increase suicidal thoughts or actions in some children, teenagers, or
young adults within the first
few months of treatment or when the dose is changed.
•
Depression or other serious mental illnesses are the most important
causes of suicidal thoughts or
actions.
•
Watch for these changes and call your healthcare provider right away
if you notice:
•
New or sudden changes in mood, behavior, actions, thoughts, or
feelings, especially if severe.
•
Pay particular attention to such changes when venlafaxine
hydrochloride extended-release capsules
are started or when the dose is changed.
Keep all follow-up visits with your healthcare provider and call
between visits if you are worried about
symptoms.
Call your healthcare provider right away if you have any of the
following symptoms, or call 911 if an
emergency, especially if they are new, worse, or worry you:
•
attempts to commit suicide
•
acting on dangerous impulses
•
acting aggressive or violent
•
thoughts about suicide or dying
•
new or worse depression
•
n
阅读完整的文件
产品特点
VENLAFAXINE HYDROCHLORIDE- VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED
RELEASE
MAJOR PHARMACEUTICALS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
VENLAFAXINE HYDROCHLORIDE
EXTENDED-RELEASE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR VENLAFAXINE
HYDROCHLORIDE EXTENDED-RELEASE CAPSULES.
VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP,
FOR ORAL USE
INITIAL U.S. APPROVAL: 1997
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_
•
•
•
INDICATIONS AND USAGE
Venlafaxine hydrochloride extended-release capsules, USP are serotonin
and norepinephrine reuptake inhibitor (SNRI)
indicated for the treatment of: (1)
•
•
•
•
DOSAGE AND ADMINISTRATION
INDICATION
(2)
STARTING DOSE
(2)
TARGET DOSE
(2)
MAXIMUM DOSE
(2)
MDD (2.1)
(2)
37.5 to 75 mg/day
(2)
75 mg/day
(2)
225 mg/day
(2)
GAD (2.2)
(2)
37.5 to 75 mg/day
(2)
75 mg/day
(2)
225 mg/day
(2)
SAD (2.3)
(2)
75 mg/day
(2)
75 mg/day
(2)
75 mg/day
(2)
PD (2.4)
(2)
37.5 mg/day
(2)
75 mg/day
(2)
225 mg/day
(2)
•
•
•
•
DOSAGE FORMS AND STRENGTHS
•
•
CONTRAINDICATIONS
•
•
INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN,
ADOLESCENTS AND YOUNG ADULTS TAKING
ANTIDEPRESSANTS (5.1)
MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS
(5.1)
VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULESARE NOT APPROVED
FOR USE IN PEDIATRIC PATIENTS
(8 .4 )
Major Depressive Disorder (MDD)
Generalized Anxiety Disorder (GAD)
Social Anxiety Disorder (SAD)
Panic Disorder (PD)
Take once daily with food (2). Capsules should be taken whole; do not
divide, crush, chew, or dissolve (2).
When discontinuing treatment, reduce the dose gradually (2.8, 5.7).
Renal impairment: reduce the total daily dose by 25% to 50% in
patients with renal impairment. Reduce the total daily
dose by 50% or more in patients undergoing dialysis or with severe
renal impairment (2.6)
Hepatic
阅读完整的文件
